MetLife Life Insurance Achieves 200,000 Contracts for Cancer Insurance 'Guard Next'

MetLife Reaches Major Milestone with 'Guard Next'

In an outstanding achievement, MetLife Life Insurance Company, under the leadership of Dirk Osteen, has successfully reached a staggering 200,000 contracts for its innovative cancer insurance product known as 'Guard Next'. Officially named the End-of-Life Cancer Insurance (No-Surrender Benefit Type), this product has been a key player in the insurance market since its launch in December 2023.

Comprehensive Protection Tailored for Cancer Treatment

'Guard Next' is meticulously designed to cover various aspects of cancer treatment, including the three major treatments: surgery, radiation therapy, and chemotherapy. Additionally, it extends its coverage to incorporate at-home medical care and palliative care, ensuring patients have access to essential pain management and neurological block treatments. The primary contract offers monthly payouts, which provides financial security and reassurance, particularly in cases where treatment may extend over a long duration.

What sets 'Guard Next' apart is its flexibility. The product includes supplementary benefits that adapt to advancements in medical technology, patient-requested treatments, and treatments not covered by public health insurance, catering to the evolving landscape of cancer care. With a high take-up rate of over 80% for its supplementary cancer treatment options, 'Guard Next' has resonated strongly with a diverse demographic, particularly among individuals in their 30s to 50s.

Addressing Public Concerns About Cancer

Cancer, consistently cited as the most feared disease in annual surveys conducted by MetLife across Japan's 47 prefectures, highlights the pressing need for comprehensive insurance solutions. The increasing complexity of treatment options—from standard therapeutic regimens combining surgery and medication to advanced medical treatments and alternative care—has made it essential for insurance products to evolve and adapt.

Recognizing this, MetLife developed 'Guard Next' with the guiding principle of supporting customers as they navigate the multifaceted challenges of cancer treatment. The insurance not only covers the necessary financial aspects but also emphasizes a commitment to customer care, providing a continuous support system throughout their treatment journey.

MetLife’s Commitment to Customer Care and Innovation

Beyond offering vital protection against unforeseen circumstances, MetLife Life Insurance seeks to be a steadfast partner in its customers' lives, assisting not just with health insurance but also in their journey toward financial stability and health wellness. The company continuously strives to deliver innovative products and services tailored to the diverse needs of its clients. Moving forward, MetLife is dedicated to fulfilling its responsibilities to contribute to a more certain future for its customers.

Founded in 1973 as Japan's first foreign life insurance company, MetLife has grown into one of the world’s leading life insurance groups, acting as the Japanese arm of MetLife, Inc. Through various sales channels, they offer a broad range of innovative products that are designed to mitigate risks faced by individual and corporate clients alike. For more information about MetLife and their offerings, please visit the official website at MetLife Japan.